Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SULFINPYRAZONE vs PRINCIPEN W/ PROBENECID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Competitive inhibitor of tubular organic anion transport, increasing uric acid excretion; also inhibits platelet aggregation.
Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) and inhibiting transpeptidase activity. Probenecid competitively inhibits renal tubular secretion of ampicillin, increasing its plasma concentration and duration.
Chronic gouty arthritis,Hyperuricemia,Off-label: Prevention of gout flares during initiation of allopurinol
Respiratory tract infections,Urinary tract infections,Meningitis,Septicemia,Endocarditis,Gonorrhea (uncomplicated)
100-200 mg orally twice daily, initially, then increase to 200-400 mg twice daily.
1.5-3 g IM q6h (20 mg/kg/day probenecid component).
2-5 hours (terminal elimination half-life; prolonged in renal impairment to up to 10 hours)
Ampicillin: 1-1.8 hours (prolonged to 4-6 hours with probenecid due to reduced renal clearance). Probenecid: 6-12 hours. Clinical context: extended half-life allows less frequent dosing.
Primarily hepatic via oxidation and conjugation; major metabolite is sulfinpyrazone sulfide.
Ampicillin is metabolized by hydrolysis to penicilloic acid; probenecid undergoes hepatic metabolism via glucuronidation and oxidation.
Renal: ~90% (50% unchanged, 50% as glucuronide and other metabolites); Biliary/fecal: ~10%
Renal: ~60-80% of ampicillin excreted unchanged in urine via tubular secretion and glomerular filtration; probenecid reduces this to ~20-30%. Biliary/fecal: minor, <10%.
98-99% (primarily to albumin)
Ampicillin: 15-25% bound to albumin. Probenecid: 85-95% bound to albumin.
0.15-0.25 L/kg (low Vd, consistent with high protein binding and limited tissue distribution)
Ampicillin: 0.3-0.4 L/kg (distributes well into extracellular fluid, low CNS penetration unless inflamed meninges).
Oral: 80-90% (well absorbed; decreased with food)
Oral: 30-50% for ampicillin (enhanced by probenecid? probenecid does not significantly alter ampicillin absorption). Probenecid: nearly 100% oral.
GFR >50 m L/min: no adjustment. GFR 10-50 m L/min: reduce dose by 50%. GFR <10 m L/min: avoid use.
Cr Cl 30-50 m L/min: 1.5 g IM q8h; Cr Cl 10-29 m L/min: 1.5 g IM q12h; Cr Cl <10 m L/min: 1.5 g IM q24h.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
No adjustment required for mild to moderate impairment. Severe impairment (Child-Pugh C): consider reducing dose by 25-50%.
Safety and efficacy not established; use not recommended.
Children 2-12 years: 50 mg/kg/day IM in 4 divided doses (probenecid component 25 mg/kg/day). Maximum single dose 2 g.
Start at lower end of dosing range (100-200 mg daily) and titrate cautiously due to increased risk of renal impairment and drug interactions.
Reduce dose based on renal function; avoid if Cr Cl <30 m L/min due to probenecid accumulation. Monitor for CNS toxicity.
None.
None.
Risk of acute gouty attacks during initial therapy,Uricosuric effect may lead to urolithiasis; maintain adequate hydration and urine alkalinization,Possible cross-allergenicity with sulfonamides,Monitor renal function and complete blood counts
Hypersensitivity reactions including anaphylaxis,Severe cutaneous adverse reactions (SCARs),C. difficile-associated diarrhea,Renal impairment (dose adjustment for ampicillin),Sodium overload with high doses,Allergic cross-reactivity with cephalosporins
Active peptic ulcer disease,Known hypersensitivity to sulfinpyrazone or sulfonamides,Severe hepatic or renal impairment
Hypersensitivity to penicillins or probenecid,History of cholestyramine or uricosuric agent hypersensitivity,Severe renal impairment (Cr Cl < 30 m L/min) for probenecid-containing products,Blood dyscrasias or uric acid calculi (probenecid)
Avoid high-purine foods (e.g., organ meats, anchovies, sardines, beer) as they may reduce efficacy. Maintain adequate hydration; alcohol consumption should be minimized as it can increase uric acid levels.
Take with food or milk to reduce gastrointestinal upset. Avoid high-fat meals as they may delay absorption of ampicillin. Probenecid is not affected by food; however, maintain adequate hydration to prevent crystalluria.
Sulfinpyrazone is contraindicated in pregnancy. Animal studies have shown teratogenic effects, and there are no adequate human studies. First trimester exposure may carry a risk of congenital malformations. Second and third trimester use may cause adverse fetal effects including premature closure of the ductus arteriosus, oligohydramnios, and renal dysfunction.
FDA Pregnancy Category B: No evidence of risk in humans. Ampicillin crosses placenta; probenecid crosses placenta but no teratogenicity reported. First trimester: No known teratogenic effects. Second/third trimester: Use caution due to potential for altered fetal gut flora. Peripartum: Risk of kernicterus in neonates if maternal hyperbilirubinemia.
Sulfinpyrazone is excreted into breast milk in small amounts. The M/P ratio is unknown. Due to the risk of serious adverse reactions in nursing infants, including the potential for kernicterus in jaundiced infants, use during breastfeeding is not recommended.
Ampicillin excreted in breast milk in low levels (M/P ratio 0.02-0.1); probenecid probably excreted but data limited. Compatible with breastfeeding; monitor infant for diarrhea, rash, or candidiasis. Theoretical risk of kernicterus in jaundiced infants if probenecid displaces bilirubin.
No specific dose adjustments have been established. Due to increased renal blood flow and glomerular filtration rate during pregnancy, pharmacokinetics may be altered, but no dose recommendations are available. Sulfinpyrazone is not recommended for use in pregnancy.
Increased renal clearance in pregnancy may reduce ampicillin levels; consider higher doses or more frequent intervals for severe infections. Probenecid dose adjustment not typically required, but monitor for efficacy. Use standard doses for UTI unless resistant organisms suspected.
Sulfinpyrazone is a uricosuric agent used for chronic gout; avoid in acute gout attack. Monitor renal function and uric acid levels. Contraindicated in peptic ulcer disease due to GI irritation. May potentiate warfarin and sulfonylureas; adjust doses accordingly.
Principen w/ Probenecid combines ampicillin, a broad-spectrum penicillin, with probenecid to prolong ampicillin serum levels by inhibiting renal tubular secretion. Use in penicillin-allergic patients is contraindicated. Probenecid may reduce excretion of other drugs (e.g., methotrexate, NSAIDs). Monitor renal function; probenecid is contraindicated in patients with uric acid kidney stones or blood dyscrasias. Administer with food if GI upset occurs. Synergistic with aminoglycosides but physically incompatible; do not mix in IV solutions.
Take with food or milk to reduce GI upset.,Drink plenty of fluids (at least 2-3 liters daily) to prevent kidney stones.,Avoid aspirin and other salicylates as they reduce effectiveness.,Report any signs of bleeding, bruising, or abdominal pain immediately.,Do not stop abruptly; discuss with your doctor.
Take this medication exactly as prescribed, even if you feel well.,Complete the full course to prevent antibiotic resistance.,May cause diarrhea; contact your doctor if it is severe or contains blood.,Avoid alcohol while taking this medication.,Inform your doctor if you have kidney disease, gout, or a history of penicillin allergy.,Probenecid may increase effects of warfarin; monitor for bleeding.,Drink plenty of fluids to prevent kidney stones while on probenecid.
"Tolvaptan, a vasopressin V2 receptor antagonist, may increase the serum concentration of sulfinpyrazone, a uricosuric agent, primarily through inhibition of OATP1B1/1B3 and possibly other hepatic uptake transporters. This interaction can lead to elevated sulfinpyrazone levels, raising the risk of adverse effects such as renal impairment or hypersensitivity reactions. Careful monitoring and dose adjustment of sulfinpyrazone are recommended when coadministered with tolvaptan."
"Rifaximin, a non-systemic antibiotic primarily acting in the gastrointestinal tract, is a substrate of P-glycoprotein (P-gp) and may induce P-gp expression. Sulfinpyrazone, a uricosuric agent and P-gp inhibitor, can increase the bioavailability and systemic exposure of rifaximin by inhibiting its efflux transport. This interaction may lead to elevated rifaximin serum concentrations, potentially increasing the risk of systemic adverse effects such as Clostridioides difficile infection or hepatic impairment, though clinical data on this specific combination are limited."
"Colchicine may increase the serum concentration of sulfinpyrazone, a uricosuric agent, potentially enhancing its therapeutic effect and risk of toxicity. This interaction is likely mediated by colchicine's inhibition of hepatic cytochrome P450 enzymes and/or interference with biliary excretion of sulfinpyrazone. Clinically, this could lead to elevated sulfinpyrazone levels, increasing the risk of adverse effects such as gastrointestinal disturbances, hypersensitivity reactions, or renal impairment."
"Edoxaban, a direct factor Xa inhibitor, may inhibit organic anion transporters (OATs) involved in the renal excretion of probenecid, leading to increased probenecid plasma concentrations. Elevated probenecid levels can enhance its uricosuric effect and potentially increase the risk of adverse effects such as gastrointestinal disturbances and hypersensitivity reactions. Clinicians should be aware of this interaction when coadministering these agents, particularly in patients with renal impairment."
"Acemetacin, a nonsteroidal anti-inflammatory drug (NSAID) and prodrug of indomethacin, reduces renal clearance of probenecid by inhibiting tubular secretion and possibly competing for organic anion transporters. This leads to increased plasma concentrations of probenecid, prolonging its half-life and enhancing its uricosuric effect. Clinically, this interaction may result in elevated risk of probenecid toxicity, including gastrointestinal discomfort, rash, or rare blood dyscrasias, while also potentially increasing the anti-inflammatory effects of acemetacin."
"Cilostazol, a phosphodiesterase III inhibitor, can inhibit the renal tubular secretion of probenecid, a uricosuric agent, thereby decreasing its clearance and increasing its serum concentration. This elevation may potentiate the effects and toxicity of probenecid, including an increased risk of uric acid nephropathy and gastrointestinal disturbances. The interaction is of particular concern in patients with renal impairment or those receiving concurrent nephrotoxic drugs."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SULFINPYRAZONE vs PRINCIPEN W/ PROBENECID, answered by our medical review team.
SULFINPYRAZONE is a Uricosuric that works by Competitive inhibitor of tubular organic anion transport, increasing uric acid excretion; also inhibits platelet aggregation.. PRINCIPEN W/ PROBENECID is a Uricosuric that works by Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) and inhibiting transpeptidase activity. Probenecid competitively inhibits renal tubular secretion of ampicillin, increasing its plasma concentration and duration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SULFINPYRAZONE and PRINCIPEN W/ PROBENECID depend on the specific clinical indication. These are both Uricosuric agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SULFINPYRAZONE is: 100-200 mg orally twice daily, initially, then increase to 200-400 mg twice daily.. The standard adult dose of PRINCIPEN W/ PROBENECID is: 1.5-3 g IM q6h (20 mg/kg/day probenecid component).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SULFINPYRAZONE and PRINCIPEN W/ PROBENECID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SULFINPYRAZONE is classified as Category A/B. Sulfinpyrazone is contraindicated in pregnancy. Animal studies have shown teratogenic effects, and there are no adequate human studies. First trimester exposure may carry a risk of. PRINCIPEN W/ PROBENECID is classified as Category A/B. FDA Pregnancy Category B: No evidence of risk in humans. Ampicillin crosses placenta; probenecid crosses placenta but no teratogenicity reported. First trimester: No known teratoge. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.